TY - JOUR AU - Kanamala Arun Chand Roby, AU - Priyanka Singamsetty, AU - Gundra Tejaswi, AU - Avula Sai Poojitha, AU - Likitha K, AU - Kudipudi Harinadha Baba, PY - 2022/09/19 Y2 - 2024/03/28 TI - A Case Study on Diabetic Neuropathy JF - Future Journal of Pharmaceuticals and Health Sciences JA - Fut J. Pharm & H. Sci VL - 2 IS - 4 SE - Case Report DO - 10.26452/fjphs.v2i4.318 UR - https://pharmasprings.com/fjphs/article/view/318 SP - 283-287 AB - <p>For the past nine years, a 54-year-old woman has had decreased glucose tolerance. A low dose of an angiotensin-converting enzyme inhibitor is used to treat her sole other medical problem, hypertension (ACE) &amp; Metformin + Vilgagliptin 50/500mg. She has had a stress ECG every two years, and the results have always been fine. During normal lab tests, she had a positive result for glucose intolerance. The first step in treating diabetic neuropathy is glucose control once the condition has been identified. Rigid insulin management dramatically decreased the likelihood of developing neuropathy, according to research by the Diabetes Complications and Control Trial Research Group. Even in patients with "excellent" blood glucose control, stricter management may result in improvements or a slowdown of the progression of neuropathy symptoms. Her vitamin B12 levels were found to be insufficient. She was taking a vitamin supplement containing folate, therefore there was no indication that she had macrocytic anemia. B12 therapy started for the patient. She claimed that although her neurological issues had only somewhat improved after 4 months of therapy.</p> ER -